Search for Clinical Trial Results
Clear Cell Renal Cell Carcinoma - 29 Studies Found
Status | Study |
Terminated |
Study Name: Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Condition:
Date: 2008-08-01 Interventions: |
Completed |
Study Name: Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2005-09-12 Interventions:
|
Recruiting |
Study Name: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer Condition:
Date: 2012-08-24 Interventions: |
Not yet recruiting |
Study Name: Study to Evaluate Efficacy and Safety of Sunitinib in Patients With Renal Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment Condition: Clear Cell Renal Carcinoma Date: 2017-02-23 Interventions: Drug: Sunitinib Sunitinib 50 mg/d |
Recruiting |
Study Name: A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma Condition:
|
Recruiting |
Study Name: Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2016-01-20 Interventions:
|
Completed |
Study Name: Investigating Patient Satisfaction With Oral Anti-Cancer Treatment Condition: Clear Cell Renal Cell Carcinoma Date: 2014-07-03 |
Completed |
Study Name: Value of Various Chemokines in the Detection and Follow up of RCC Condition: Clear Cell Renal Cell Carcinoma Date: 2013-10-30 Interventions: Other: patients with renal cell carcinoma Chemokines that may be elevated in patients with RCC |
Completed |
Study Name: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Condition: Clear Cell Renal Cell Carcinoma Date: 2013-01-08 Interventions: Drug: Dovitinib Patients will be treated with dovitinib (5 |
Completed |
Study Name: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Condition: Metastatic Clear Cell Renal Cell Carcinoma Date: 2013-11-29 Interventions: Drug: Lu-177-DOTA-girentuximab Drug: In-111-DOTA-girentuxi |